| February 7, 2013 | News for the transfusion medicine and cellular therapy community |
 |  |
- Stem cells survive being "printed" in 3D pattern
Researchers from the University of Edinburgh in Scotland developed a three-dimensional printer that can gently place living stem cells in uniform droplets, a step toward the possible construction of tissues and organs. More than 95% of the cells were alive a day following printing and more than 89% were alive after three days while maintaining a marker for pluripotency. The findings were reported in the journal Biofabrication. LiveScience.com
(2/5)     
|
|
How much do you hate your anti-Fyb?
Tired of sub-par reactions? Quotient has a newly approved anti-Fyb, as well as hard-to-find Anti-s, Anti-Wra and other rare antisera that are worth a try. Find out how the one company focused on manual testing can serve you in 2013 and beyond.
|
| Science & Health |  |  |
|
| Emerging Trends | | |
|
- 6 trends that will shape the health IT landscape this year
 Six key trends are expected to affect health groups this year: the expedited growth of value-based purchasing and accountable care organizations; more mergers and acquisitions; greater emphasis on data; increased sales of revenue cycle systems; enhanced focus on ICD-10; and a shortage of skilled health IT workers. These trends will be driven by EHR meaningful use and other factors. Healthcare Informatics online
(2/4)
| Industry News & Practice | | |
|
- J&J unit gains 510(k) clearance for surgical sealer
Ethicon, a Johnson & Johnson unit, has been cleared by the FDA to market its Enseal G2 Articulating system. The device, which is used to aid surgeons in accessing tight cavities and minimizing internal bleeding, improves on the company's original Enseal system with the ability to flex around bodily structures. MassDevice.com (Boston)
(2/6)
| Government & Regulatory | | |
|
- FDA issues warning against deceptive flu products
The FDA has released a report warning the public against fraudulent flu products that carry unproven claims about curing, treating or preventing the flu. The warning covers drugs, nasal sprays, devices, foods and dietary supplements. The FDA said it has yet to approve any over-the-counter treatment that can cure or prevent the condition, and there are no approved generic formulations of Tamiflu or Relenza. PhysiciansBriefing.com/HealthDay News
(2/5)
| Association News | | |
|
-
Reminder: "Neonatal Transfusion Guidance" available in AABB Marketplace
"Neonatal Transfusion Guidance" -- a digital download -- is available in the AABB Marketplace. The publication addresses the unique requirements for neonatal transfusion that affect processes and procedures in the continuum from collection and selection of blood components to the methods of administration.
| SmartQuote | | |
|
 | I am never bored anywhere: being bored is an insult to oneself."
--Jules Renard,
French author
|
| |
| |
|
Read more at SmartBrief.com |
|
A powerful website for SmartBrief readers including:
|
|
|
|
| |
| |
| | Recent AABB SmartBrief Issues:
- Wednesday, February 06, 2013
- Tuesday, February 05, 2013
- Monday, February 04, 2013
- Friday, February 01, 2013
- Thursday, January 31, 2013
| | | Lead Editor: Tom Parks
Managing Editor: Jennifer Garfinkel
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | |
| |
|
| © 1999-2013 SmartBrief, Inc.® Legal Information |
|
Some state pharmacy boards are claiming authority to regulate pharmacy benefit managers and drug compounders. Pharmacists who sit on state pharmacy boards face a conflict of interest in overseeing entities whose success or failure affects board members' own incomes, Edward C. Lawrence writes. 
